Exicure, Inc.

NasdaqCM:XCUR Stock Report

Market Cap: US$9.2m

Exicure Dividends and Buybacks

Dividend criteria checks 0/6

Exicure does not have a record of paying a dividend.

Key information

n/a

Dividend yield

0%

Buyback Yield

Total Shareholder Yield0%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Analysis Article • Aug 29

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure, Inc. ( NASDAQ:XCUR ) shareholders won't be pleased to see that the share price has had a very rough month...
Seeking Alpha • Sep 26

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Early-stage biotech Exicure (NASDAQ:XCUR) on Monday announced a host of strategic actions, including a workforce reduction of about 66% and a halt to its research and development activities and its pre-clinical studies. The company estimated that it will incur total expenses relating to the restructuring of about $0.5M, adding that it expects the strategic actions to extend its cash runway into Q2 2023. XCUR said it would explore divestiture options for its SCN9A clinical program developing candidates for neuropathic pain, as results from a recent animal study did not meet "desired target engagement levels." In Monday's statement, XCUR also said it had entered into a private placement in public equity (PIPE) financing with existing investor CBI USA for anticipated gross proceeds of about $5.4M. CBI USA would also hold a controlling stake in XCUR equivalent to about 50.4% of the total voting power upon satisfaction of certain deal closing conditions. XCUR stock earlier closed +10.4% at $1.70.
Seeking Alpha • Aug 15

Exicure Q2 GAAP loss per share narrows, revenue up

Exicure press release (NASDAQ:XCUR): Q2 GAAP EPS of -$1.66 (vs. -$4.86 Y/Y). Revenue of $2.5M (vs. $0.1M Y/Y). Shares -9.05% AH.
Seeking Alpha • Jul 20

Exicure regains compliance with Nasdaq's minimum bid price requirement

Nasdaq has informed Exicure (NASDAQ:XCUR) that the biotechnology company has regained compliance with the stock exchange's $1.00 per share minimum bid price requirement. XCUR is now in compliance with all applicable listing standards, and the company's shares will continue to be listed and traded on the Nasdaq Capital Market. The shares closed at $1.72 on July 20. Source: Press Release
Seeking Alpha • Jun 29

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Exicure (NASDAQ:XCUR) announces that following the implementation of a one-for-thirty reverse stock split, the company’s common stock will begin trading on a split-adjusted basis on Nasdaq effective open of Thursday, June 30, 2022. On December 30, 2021, Nasdaq notified the company that it no longer satisfied the minimum bid price requirement as the bid price for the stock had closed below $1.00 per share for the previous thirty consecutive business days. Stock dumps ~31%.
Analysis Article • Aug 25

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if XCUR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XCUR's dividend payments have been increasing.

Dividend Yield vs Market

Exicure Dividend Yield vs Market
How does XCUR dividend yield compare to the market?
SegmentDividend Yield
Company (XCUR)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.1%
Industry Average (Biotechs)2.1%
Analyst forecast (XCUR) (up to 3 years)n/a

Notable Dividend: Unable to evaluate XCUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XCUR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate XCUR's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as XCUR has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 20:11
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exicure, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Keay NakaeChardan Capital Markets, LLC
Yatin SunejaGuggenheim Securities, LLC